213Bi-FAPI-46

213Bi-FAPI-46 is a radiopharmaceutical drug candidate composed of the fibroblast activation protein inhibitor (FAPI)-46 labeled with the alpha-emitting radioisotope bismuth-213. It is designed for targeted radionuclide therapy (RPT) of solid tumors by binding to fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts in the tumor microenvironment. The mechanism involves delivering cytotoxic alpha radiation directly to FAP-expressing cells, thereby damaging tumor stroma and potentially enhancing anti-tumor effects. Early clinical studies have shown that fractionated administration of 213Bi-FAPI-46 was well tolerated and led to partial response or stable disease in some patients with metastatic solid tumors, including colon, anal, breast, and prostate cancers[1][2]. The short half-life of bismuth-213 (about 46 minutes) allows for rapid delivery and clearance. FAPI ligands such as FAPI-46 are under development by academic groups including Heidelberg University and companies like Sofie Biosciences/ABX[6][8].

Other names

FAPI-46FAPI46FAPI 46